Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1995 2
1996 1
1998 2
1999 1
2000 2
2001 2
2002 3
2003 4
2004 3
2006 2
2008 2
2009 1
2014 1
2015 1
2016 2
2017 5
2018 6
2019 7
2020 2
2021 3
2022 7
2023 5
2024 5
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. Conroy T, et al. N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775. N Engl J Med. 2018. PMID: 30575490 Clinical Trial.
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, Mitry E, Biagi JJ, Evesque L, Artru P, Lecomte T, Assenat E, Bauguion L, Ychou M, Bouché O, Monard L, Lambert A, Hammel P; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. Conroy T, et al. JAMA Oncol. 2022 Nov 1;8(11):1571-1578. doi: 10.1001/jamaoncol.2022.3829. JAMA Oncol. 2022. PMID: 36048453 Free PMC article. Clinical Trial.
Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial.
Adam R, Piedvache C, Chiche L, Adam JP, Salamé E, Bucur P, Cherqui D, Scatton O, Granger V, Ducreux M, Cillo U, Cauchy F, Mabrut JY, Verslype C, Coubeau L, Hardwigsen J, Boleslawski E, Muscari F, Jeddou H, Pezet D, Heyd B, Lucidi V, Geboes K, Lerut J, Majno P, Grimaldi L, Levi F, Lewin M, Gelli M; Collaborative TransMet group. Adam R, et al. Among authors: granger v. Lancet. 2024 Sep 21;404(10458):1107-1118. doi: 10.1016/S0140-6736(24)01595-2. Lancet. 2024. PMID: 39306468 Clinical Trial.
Irreversible electroporation augments checkpoint immunotherapy in prostate cancer and promotes tumor antigen-specific tissue-resident memory CD8+ T cells.
Burbach BJ, O'Flanagan SD, Shao Q, Young KM, Slaughter JR, Rollins MR, Street TJL, Granger VE, Beura LK, Azarin SM, Ramadhyani S, Forsyth BR, Bischof JC, Shimizu Y. Burbach BJ, et al. Among authors: granger ve. Nat Commun. 2021 Jun 23;12(1):3862. doi: 10.1038/s41467-021-24132-6. Nat Commun. 2021. PMID: 34162858 Free PMC article.
Rocuronium-specific antibodies drive perioperative anaphylaxis but can also function as reversal agents in preclinical models.
Dejoux A, Zhu Q, Ganneau C, Goff OR, Godon O, Lemaitre J, Relouzat F, Huetz F, Sokal A, Vandenberghe A, Pecalvel C, Hunault L, Derenne T, Gillis CM, Iannascoli B, Wang Y, Rose T, Mertens C, Nicaise-Roland P; NASA Study Group; England P, Mahévas M, de Chaisemartin L, Le Grand R, Letscher H, Saul F, Pissis C, Haouz A, Reber LL, Chappert P, Jönsson F, Ebo DG, Millot GA, Bay S, Chollet-Martin S, Gouel-Chéron A, Bruhns P. Dejoux A, et al. Sci Transl Med. 2024 Sep 11;16(764):eado4463. doi: 10.1126/scitranslmed.ado4463. Epub 2024 Sep 11. Sci Transl Med. 2024. PMID: 39259810 Free article.
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial.
Walter T, Lievre A, Coriat R, Malka D, Elhajbi F, Di Fiore F, Hentic O, Smith D, Hautefeuille V, Roquin G, Perrier M, Dahan L, Granger V, Sobhani I, Mineur L, Niccoli P, Assenat E, Scoazec JY, Le Malicot K, Lepage C, Lombard-Bohas C. Walter T, et al. Among authors: granger v. Lancet Oncol. 2023 Mar;24(3):297-306. doi: 10.1016/S1470-2045(23)00001-3. Epub 2023 Feb 2. Lancet Oncol. 2023. PMID: 36739879 Clinical Trial.
[Miraculous catch by neutrophils NETs].
Granger V, de Chaisemartin L, Chollet-Martin S. Granger V, et al. Med Sci (Paris). 2014 May;30(5):544-9. doi: 10.1051/medsci/20143005018. Epub 2014 Jun 13. Med Sci (Paris). 2014. PMID: 24939542 Free article. Review. French.
Immediate hypersensitivity to COVID-19 vaccines: Focus on biological diagnosis.
Nicaise-Roland P, Granger V, Soria A, Barbaud A, Pallardy M, Chollet-Martin S, de Chaisemartin L. Nicaise-Roland P, et al. Among authors: granger v. Front Allergy. 2022 Sep 30;3:1007602. doi: 10.3389/falgy.2022.1007602. eCollection 2022. Front Allergy. 2022. PMID: 36249342 Free PMC article. Review.
Cytosolic proliferating cell nuclear antigen (PCNA) orchestrates neutrophil hyperactivation in COVID-19.
Formiga RO, Pesenti L, de la Héronnière FC, Ladjemi MZ, Stojkov D, Yousefi S, Frachet P, Krafft L, Tiberio L, Bosisio D, Andrieu M, Many S, Karunanithy V, Bailly K, Dhôte T, Saraceni-Tasso G, Castel M, Rousseau C, Starick MR, da Rocha EL, Lombardi EP, Almeida CJLDR, Ramos ADS, Cunha FQ, Alves-Filho JC, Nóbrega NRC, Gonçalves MR, Queiroz-Junior CM, Lima Batista V, Teixeira MM, Granger V, Chollet-Martin S, Chaisemartin L, Mouthon L, Hosmalin A, Hurtado-Nedelec M, Martin C, Spiller F, Simon HU, Tamassia N, Cassatella MA, Pène F, Vogl T, Burgel PR, Costa VV, Witko-Sarsat V. Formiga RO, et al. Among authors: granger v. Proc Natl Acad Sci U S A. 2025 Oct 28;122(43):e2503667122. doi: 10.1073/pnas.2503667122. Epub 2025 Oct 21. Proc Natl Acad Sci U S A. 2025. PMID: 41118208
64 results